Literature DB >> 19845235

The effectiveness and safety of intra-articular injection of sodium hyaluronate (500-730 kDa) in the treatment of patients with painful knee osteoarthritis.

Vajara Phiphobmongkol1, Vudhipong Sudhasaneya.   

Abstract

BACKGROUND: Sodium Hyaluronate (500-730 kilodalton (kDa); Hyalgan) is recommended to administer intra-articularly once a week for 3-5 weeks in patients with osteoarthritis of the knee which its efficacy has been shown, from many clinical studies, to persist for at least 6 months. However only a few studies were done in Thai patients.
OBJECTIVE: To assess the efficacy and safety of intra-articular Sodium Hyaluronate, administered once a week for four weeks (four injections) in Thai patients with painful Tibio-Femoral osteoarthritis of the knee over a six-month period. MATERIAL AND
METHOD: Thirty-one patients with painful knee osteoarthritis in grade I (32.3%) and grade II (67.7%) severity on Ahlback radiological criteria from Orthopedic Clinic in Bhumibol Adulyadej Hospital were included in this study. All patients were administered with 4-weekly injections of intra-articular Sodium Hyaluronate (500-730 kDa; Hyalgan; 20mg/2ml). Only paracetamol was permitted for escape analgesia. The efficacy parameters were the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for pain, stiffness and physical function, intake of paracetamol, and overall efficacy judgment by investigators and patients. The occurrence of adverse event was recorded at each visit.
RESULTS: After the second injection of Sodium Hyaluronate, all WOMAC index revealed the significant improvement from baseline (p < 0.05). The WOMAC-VAS for pain at baseline, Day 14, 28, 84, and 168 were 50.3, 33.3, 29.1, 23.1, and 21.4 mm respectively. At the end of study, most patients and investigators evaluated treatment efficacy as moderate to very effective. There was a decrease in paracetamol consumption from baseline until the last follow-up. Nine adverse events were recorded, which were transient events; most of them consisted of pain at injection site. No systemic or serious adverse event was reported.
CONCLUSION: The results of this study showed the efficacy and safety of 4-weekly injections of Sodium Hyaluronate in the treatment of knee osteoarthritis in Thai patients over a six-month period.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19845235

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  5 in total

1.  Obesity-related juvenile form of cartilage lesions: a new affliction in the knees of morbidly obese children and adolescents.

Authors:  Harald K Widhalm; Stefan Marlovits; Goetz H Welsch; Albert Dirisamer; Andreas Neuhold; Martijn van Griensven; Rudolf Seemann; Vilmos Vécsei; Kurt Widhalm
Journal:  Eur Radiol       Date:  2011-09-21       Impact factor: 5.315

2.  Intra-articular glenohumeral injections of HYADD®4-G for the treatment of painful shoulder osteoarthritis: a prospective multicenter, open-label trial.

Authors:  Giuseppe Porcellini; Giovanni Merolla; Nicola Giordan; Paolo Paladini; Andrea Burini; Eugenio Cesari; Alessandro Castagna
Journal:  Joints       Date:  2016-01-28

3.  Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz.

Authors:  Heng Zhang; Ke Zhang; Xianlong Zhang; Zhenan Zhu; Shigui Yan; Tiansheng Sun; Ai Guo; John Jones; R Grant Steen; Bin Shan; Jenny Zhang; Jianhao Lin
Journal:  Arthritis Res Ther       Date:  2015-03-10       Impact factor: 5.156

4.  Hyaluronic Acid Intra-Articular Injections in Patients Affected by Moderate to Severe Glenohumeral Osteoarthritis: A Prospective Randomized Study.

Authors:  G Di Giacomo; N de Gasperis
Journal:  Joints       Date:  2017-08-11

Review 5.  Intraarticular Hyaluronic Acid Preparations for Knee Osteoarthritis: Are Some Better Than Others?

Authors:  David Webner; Yili Huang; Charles D Hummer
Journal:  Cartilage       Date:  2021-05-28       Impact factor: 4.634

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.